Safety Study of a Cytotoxic Lymphocytes (CTL) Based Prostate Cancer Therapy (ALECSAT)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
CytoVac A/S
ClinicalTrials.gov Identifier:
NCT00891345
First received: April 30, 2009
Last updated: April 26, 2012
Last verified: April 2012
  Purpose

This study is a phase I study of a new cell based prostate cancer therapy (ALECSAT). In this therapy specific cells from the patient's own immune system are isolated, activated and re-administered to the patient to boost a specific immune response against the cancer cells. The aim of the study is to show safety and tolerability for this type of therapy. It is the hypothesis that the cells administered during the therapy will attack the tumour cells and in this way stop or slow down the progression of disease.


Condition Intervention Phase
Hormone-refractory Prostate Cancer
Biological: ALECSAT
Phase 1

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Prospective, Open Phase I Study to Investigate the Tolerability and Efficacy of Administering ALECSAT to Prostate Cancer Patients - a First Dose in Man Study

Resource links provided by NLM:


Further study details as provided by CytoVac A/S:

Primary Outcome Measures:
  • The primary endpoint is to show safety and tolerability for the administration of ALECSAT to enable further clinical development of the ALECSAT therapy. [ Time Frame: Within 7 weeks ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • The secondary endpoint for this study is to establish if any indications of a positive therapeutic effect on the prostate cancer may be observed. [ Time Frame: Within 7 weeks ] [ Designated as safety issue: No ]

Enrollment: 13
Study Start Date: April 2009
Study Completion Date: July 2010
Primary Completion Date: July 2010 (Final data collection date for primary outcome measure)
Intervention Details:
    Biological: ALECSAT
    Autologous activated CTL and NK-cells injected as a single intravenous injection.
Detailed Description:

This study is a prospective open phase I study to investigate the safety and tolerability of administration of a single dose of a cell based medicinal product (CBMP) ALECSAT.

ALECSAT is an autologous CBMP that is made from the patient's own blood cells. ALECSAT contains a large amount of tumour specific cytotoxic Lymphocytes (CTL) and Natural Killer (NK) cells that are isolated activated and amplified in number.

The CBMP is given as a slow i. v. injection to patients with prostate cancer. The patients are in the late stage of the disease where they have received hormone treatment but their disease is progressing.

The primary objective of the study is to observe if any side effects or tolerability issues occur as a consequence of the cell administration, secondarily it will be observed if any positive anti tumour effect may be observed. The study has the purpose to investigate whether treatment with ALECSAT in any way is toxic.

Trial Design: The study is an open, prospective phase I safety study of ALECSAT in prostate cancer patients.

A group consisting of 6 patients will be treated with ALECSAT according to the protocol. Then an interim analysis will be done. If there are no signs of significant toxicity related to the treatment, the study will continue with 8 more patients that will be included and treated with ALECSAT according to the phase I protocol. Thus this study will include a total of 14 patients.

The patients will after a single administration of ALECSAT be hospitalised for 3 days and will furthermore be followed closely for 7 weeks by 5 planned study visits, by the investigators at Urologisk Klinik at Fredrikssund Hospital.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Hormone-refractory prostate cancer patients
  • Three consecutive rises of PSA min. 2 weeks apart, resulting in at least two 50% increases over the PSA nadir.
  • Antiandrogen withdrawal for at least 4 weeks, or
  • PSA progression despite secondary hormonal manipulations, or
  • Progression of osseous or soft tissue lesions.
  • Serum castration levels of testosterone.
  • Be capable of understanding the information and giving informed consent.
  • Expected survival time (life expectancy) of over 4 months.
  • Adequate performance status (WHO / ECOG Performance status score 2 or less).

Exclusion Criteria:

  • Patients with a low blood count (haemoglobin < 6.0 mmol/l).
  • Patients with lymphocyte-numbers below 0.8.
  • Patients known to be HIV and/or hepatitis positive i.e. patients positive in tests for anti-HIV-1/2; HBsAg, anti-HBc and Anti-HCV.
  • Patients known to have syphilis i.e. being positive in a Treponema Pallidum test.
  • Patients with uncontrolled serious bacterial, viral, fungal or parasitic infection.
  • Patients must have no clinically significant autoimmune disorders or conditions of immune suppression.
  • Patients that have been treated with corticosteroids (steroid hormones) or bisphosphonates or have been in chemotherapy or radiation treatment one month prior to inclusion in the clinical trial.
  • Fertile patients.
  • Patients that have received blood transfusions within 48 hours prior to donation of blood for ALECSAT production.
  • Patients must not have been included in other clinical trials 6 weeks prior to inclusion in the trial or be enrolled in other clinical trials during the ALECSAT clinical trial.
  • Any medical condition that will render participation in the study risky or, according to the investigator in charge, will make the assessment of side-effects difficult.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00891345

Locations
Denmark
Urological Clinic, Frederikssunds Hospital
Frederikssund, Denmark, DK-3600
Sponsors and Collaborators
CytoVac A/S
Investigators
Principal Investigator: Hans-Henrik Meyhoff, MD Urologisk Klinik, Frederikssund Hospital, Frederikssundsvej 30, 3600 Frederikssund
  More Information

No publications provided

Responsible Party: CytoVac A/S
ClinicalTrials.gov Identifier: NCT00891345     History of Changes
Other Study ID Numbers: CV001
Study First Received: April 30, 2009
Last Updated: April 26, 2012
Health Authority: Denmark: Danish Medicines Agency

Keywords provided by CytoVac A/S:
hormone-refractory prostate cancer
Immunotherapy

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Genital Diseases, Male
Prostatic Diseases

ClinicalTrials.gov processed this record on July 20, 2014